US03475V1017 - Common Stock
Investors didn't like the medical technology company's fiscal 2025 Q1 update.
ANGO stock results show that AngioDynamics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2024.
ANGO stock results show that AngioDynamics missed analyst estimates for earnings per share and missed on revenue for the third quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips AngioDynamics (NASDAQ:ANGO) just reported results for the third quarter of 2024...
We're diving into the biggest pre-market stock movers that traders are going to want to keep an eye on for Thursday morning!